We have previously demonstrated that a purified bacterially synthesized ElA 289-amino-acid protein is capable of stimulating transcription from the promoters of genes transcribed by RNA polymerase II in vitro (R. Spangler, M. Bruner, B. Dalie, and M. L. Harter, Science 237:1044-1046. In this study, we show that this protein is also capable of transactivating in vitro the adenovirus virus-associated (VA1) RNA gene transcribed by RNA polymerase UI. Pertinent to the transcription of this gene is the rate-limiting component, TFIIIC, which appears to be of two distinct forms in uninfected HeLa cells. The addition of an oligonucleotide containing a TFIIIC binding site to HeLa whole-cell extracts inhibits VAT transcription by sequestering TFIIIC. However, the addition of purified ETA to extracts previously challenged with the TFIIIC oligonucleotide restores the level of VAT transcription. When included in the same reaction, an ElA-specific monoclonal antibody reverses the restoration. Incubation of purified ETA with either HeLa cell nuclear or whole-cell extracts alters the DNA-binding properties of TFIIIC as detected by gel shift assays. This alteration does not occur if ElA-specific antibody and ETA protein are added simultaneously to the extract. In contrast, the addition of this antibody to extracts at a later time does not reverse the alteration observed in the TFIIIC binding activities. Never at any time did we note the formation of novel TFIIIC-promoter complexes after the addition of ETA to nuclear extracts. These results clearly establish that ETA mediates its effect on VAT transcription through TFIIIC in a very rapid yet indirect manner. The results also establish that a bacterially produced ETA protein can directly participate in RNA polymerase II transcription without the requirement of celiular protein synthesis or other viral proteins.
The adenovirus 289-amino-acid ElA protein is well recognized for its ability to stimulate transcription from a number of viral and cellular promoters (reviewed in reference 7). The promoters responsive to this protein are not limited to genes transcribed by RNA polymerase II but also include those belonging to genes transcribed by RNA polymerase III (POLIII) (18, 19) . In spite of what is known, it is still unclear exactly how the ElA protein is able to up-regulate transcription from the promoters of these two classes of genes. For instance, although ElA binds directly to DNA, as do many other transcriptional factors, it appears to do so only in a nonspecific fashion (4, 21) . Furthermore, comparisons of wild-type and partially mutagenized promoters have not as yet identified an ElA inducible site apart from that which is required for full basal level transcription (20, 26, 33) . Thus, it would seem that ElA does not act alone in stimulating transcription but instead acts indirectly, perhaps by affecting the levels of host-cell transcriptional factors (18, 20) . However, it now appears unlikely that cellular protein synthesis is important to the ElA induction of class II genes, for several reasons. First, a purified bacterially synthesized ElA protein (2) and a peptide of ElA with transactivating activity (32) have recently proven to be quite capable of stimulating transcription from promoters in vitro (14, 37) . Second, cellular factors such as ATF and MLTF, which appear to participate in ElA transactivation, remain unchanged in concentration during adenovirus infection (7, 25, 36) . Taken together, these observations lead to the notion that certain cellular factors of class II genes may in themselves be directly affected by ElA. In fact, the prominent TATAbinding factor (i.e., TFIID) as well as the E4F, ATF, and E2F promoter factors all appear to be targets for E1A-mediated induction (15, 25, 27, 35) , and both E2F and E4F appear to become modified by phosphorylation during adenovirus infection (1, 34) . More recent studies have revealed a family of cellular ATF factors, one of which is thought to function by recruiting ElA to the promoter (29) .
The only class III gene factor which appears to change during adenovirus infection is TFIIIC (18, 19, 40) . Apart from POLIII, this factor, together with another factor termed TFIIIB, is the required component for in vivo transcription of the tRNA and adenovirus virus-associated (VA1) RNA genes (10, 19, 24) . Both of these genes are unique in that they contain two highly conserved intragenic elements, termed the A and B blocks, which constitute internal transcriptional control regions (8, 10) . TFIIIC, which has been defined as the rate-limiting factor of class III transcription, binds with high affinity to the internal B-block region (centered at about +60 relative to the start site) of both genes (8, 19, 24) . However, it appears that TFIIIC is also capable of binding, albeit weakly, to the A-block region, but only under conditions that favor high protein concentrations (3, 39) . The success of TFIIIB in becoming sequestered into a stable transcription complex on a mammalian class III gene seems to depend on its association (via protein-protein interaction) with TFIIIC (3, 8, 19) and not on its binding to upstream DNA. Transcription of the tRNA and VAl RNA genes is dramatically increased in adenovirus-infected cells (11, 19, 38) , and the ElA proteins appear to play a role in this process (18, 19, 29) . Fractionation of these cells demonstrates an ElA-dependent stimulating activity in a fraction that contains TFIIIC, suggesting that this factor may be the target for ElA (18, 19, 29 [17] ) and isolated by affinity chromatography on protein A-Sepharose as described by the manufacturer (Pharmacia). The Ab-1 monoclonal antibody specific for the adenovirus type 5 E1B 21-kDa protein was acquired from Oncogene Science, Inc. Plasmids and oligonucleotides. The plasmid pVA* used for in vitro transcription contains the adenovirus type 2 HindIII fragment (nucleotides 6232 to 11559 [13] ) inserted into the HindIll site of pBR322. The 129-bp XbaI-BstEII fragment containing the VAl gene for the gel retardation assays was derived from the pVA1 plasmid, which has been described elsewhere (18) and which was kindly provided by W. K. Hoeffler, Genetech, Inc.
The double-stranded TFIIIC and mutant-TFIIIC (M-TFIIIC) oligonucleotides were formed by the hybridization (16) 4 mM creatine phosphate, and 300 to 400 puM (each) ATP, CTP, and UTP. Transcription was allowed to proceed for 1 h at 30°C and was terminated by the addition of 200 pul of proteinase K buffer that contained 9.6 p.g of proteinase K, 20 mM Tris hydrochloride (pH 8.0), 10 mM EDTA, 100 mM NaCl, and 1% sodium dodecyl sulfate. The RNA was extracted once with a mixture of phenol, chloroform, and isoamyl alcohol and then precipitated with ethanol. Afterwards, the RNA pellet was resuspended in 300 RI of deionized water containing 10 ,ug of glycogen as a camer.
After three successive ethanol precipitations, the pellet was resuspended in 30 p.l of deionized formamide. One-third or one-fourth of the sample was then subjected to electrophoresis on a 6% polyacrylamide gel (acrylamide/bisacrylamide, 29:1) containing 8.3 M urea at a constant current of 55 mA.
Gels were soaked in 10% glacial acetic acid, dried, and then exposed to X-ray film (Kodak X-Omat AR) at -70°C with an intensifying screen. Relative levels of transcript were quantitated by the densitometric scanning (Bio-Rad, model 620 densitometer) of appropriately exposed autoradiograms.
In some experiments, 32P-5'-end-labeled fragments of 139 and 183 bp (derived from pUC19 with appropriate restriction endonucleases) were added to the reactions following the termination of transcription with proteinase K. This served A PURIFIED ElA ACTIVATES A CLASS III GENE IN VITRO 5299 as a control to ensure that the quantity of RNA recovered from each of the reactions was the same.
Purification of the ElA protein. Plasmid pKHAO-T, encoding an authentic adenovirus type 2 ElA protein of 289 amino acids (2, 22) , was propagated in a protease-deficient Escherichia coli strain, MC102. Growth conditions for the optimum expression of ElA in these cells, as well as its purification to near homogeneity from these cells, has been described elsewhere (2) . Once obtained, the protein was stored in small aliquots at -80°C (not more than 2 months) and diluted immediately prior to the addition to the in vitro reactions.
Gel mobility shift. The binding reactions for gel mobility shift assays were essentially carried out as previously described (9, 18) . Typically, the reactions (20 pul) contained 10 mM Tris hydrochloride (pH 7.5), 0.5 mM EDTA, 2.5 mM MgCl,, 2.5 mM dithiothreitol, 50 mM KCl, 7 ,ug of either nuclear or whole-cell extract, 2.0 ,ug of poly(dI-dC)-poly(dIdC) (Pharmacia), and about 1 ng of 3'-end-labeled probe. The VAl promoter-containing probe of 129 bp was prepared from pVA1 by digestion with Xbal and BstEII and 3'-end labeling with the Klenow fragment of DNA polymerase I (sequence grade; Boehringer Mannheim). The binding reactions were incubated for 20 to 30 min at 30°C, and afterwards the samples were run on 4% nondenaturing polyacrylamide (acrylamide/bisacrylamide, 30:1) gels at 125 V for 3 to 4 h at room temperature in a TBE buffer system (6.25 mM Tris hydrochloride [pH 7.5], 6.25 mM boric acid, 0.25 mM EDTA). Gels were then dried and exposed to X-ray film (Kodak X-Omat AR). Prior to the loading of the samples, gels were preelectrophoresed for either 15 or 20 min.
The gel shift assays with purified ElA or with ElA and M-73 monoclonal antibody were carried out in an identical manner, except that nuclear or whole-cell extracts in binding buffer, with or without added ElA or ElA and antibody, were preincubated at 4°C for 30 min prior to the addition of poly(dI-dC)-poly(dI-dC) and radioactive probe.
RESULTS
A purified EIA protein stimulates VAI transcription in vitro. We have previously shown that an ElA protein of 289 amino acids, synthesized and purified from E. coli (2, 22) , is capable of transactivating transcription from promoters of class II genes in vitro (7, 37 (37) , no change in the efficiency of the VAl transcription was observed when either of the antibodies was added to extracts without ElA, indicating that they themselves had no effect on the transcriptional events which were observed (data not shown). Thus, we conclude that our purified ElA is directly responsible for activating the VAl RNA gene in vitro. In addition, neither cellular protein synthesis nor other viral proteins are required for this stimulation.
ElA restores VAl transcription after depletion of active TFIIIC. It has been recently shown that TFIIIC can apparently assume two distinct forms, one of which becomes modified during adenovirus infection (18) . Presumably, the form that is altered in the infected cell is initially without transcriptional activity and comparatively slow in its rate of association with the VAl promoter (18) . In light of these findings, we wanted to determine the effect of purified ElA on the transcriptional capacity of whole-cell extracts selectively depleted of active TFIIIC. One of the key components of this experiment is an oligonucleotide which contains the B-block region of the VAl gene (8) , a site previously identified as being the primary recognition site for TFIIIC binding (10, 18) . We initiated experiments by titrating a fixed amount of whole-cell extract to determine the quantity of TFIIIC oligonucleotide required to block (almost completely) transcription from a subsequently added VAl template. As shown in Fig. 3A (Fig.  3C) , the activity of the VAl promoter was dramatically reduced (lane 3). The results of this part of the experiment eliminate the possibility that ElA itself is acting directly at the VAl promoter or that transactivation is occurring through a mechanism independent of TFIIIC. Taken together, these results indicate that, under these conditions, added ElA is able to directly rescue VAl transcription and that this response may be predicated on the availability of inactive TFIIIC.
Purified ElA alters the interaction of TFIIIC with its recognition site. To determine whether the observed increase in transcriptional activity of extracts supplemented with ElA correlated with a change in the binding activity of TFIIIC, we performed gel shift analysis with the use of both nuclear and whole-cell extracts. The assays shown in Fig. 4 employed a labeled VAl gene probe that extended from -30 to +99, as well as the inclusion of poly(dI-dC)-poly(dI-dC). Consistent with previous results (5, 18) , the probe formed three complexes (A, B, and C) when it was incubated with nuclear proteins of HeLa cells (Fig. 4A, lane 1) 2 to 4) .
The formations of all three complexes were compared in reactions in which the VAl probe was incubated in nuclear extracts with or without the addition of ElA (Fig. 5A) (7 ,ug) and, where indicated, an unlabeled VAl gene fragment (60-and 100-fold molar excess), a 51-bp oligonucleotide containing only the TFIIIC binding site (180-and 240-fold molar excess), or a nonspecific oligonucleotide of 48 bp (180-and 240-fold molar excess). After 30 min, the samples were directly loaded onto gels and electrophoresed. Migration of an upper (A) and a lower (B) TFIIIC-containing complex is indicated as well as an uncharacterized specific complex (C) which has been previously described (5, 18 Binding reactions containing nuclear extract (7 ,ug) and antibody had no effect on the migration of free probe in the absence of nuclear proteins (data not shown). Taken together, these results clearly indicate that ElA itself is capable of altering, either directly or indirectly, the binding activity of the VAl B-block factor, TFIIIC.
DISCUSSION
A purified ElA 289-amino-acid protein made in E. coli is capable of transactivating the adenovirus VAl RNA gene in a mammalian cell-free system. When this protein was added to uninfected HeLa whole-cell extracts, the level of transcription observed from the VAl promoter increased on an average about 4.5-fold (Fig. 1) . The degree of transactivation occurring in these experiments depended primarily on the concentration of ElA molecules. That ElA indeed participates in enhancing transcription from the VAl promoter was basically established in two ways. First, a purified 243-amino-acid ElA protein lacking the unique 46-amino-acid region was not at all efficient in activating transcription from the VAl promoter when it was added to whole-cell extracts (17a) . Second, an ElA-specific monoclonal antibody effectively reversed the stimulation of the VAl promoter when it was added to extracts at the same time as ElA (Fig. 2) . By contrast, when a monoclonal antibody specific for a protein other than ElA was added, the up-regulation of the VAl promoter by ElA was sustained, thereby ruling out the possibility that the antibodies themselves were affecting the transcriptional machinery. These observations indicate that the ElA protein directly participates in stimulating transcription from the VAl promoter. They also indicate that there is no requirement for the synthesis of other cellular factors or other viral proteins. Although these conclusions represent an important step in defining some of the mechanisms by which ElA transactivates class III genes, they are not unique, since similar conclusions were reached after studying the activities of purified ElA on class II genes in vitro (37) . This scenario in itself may provide further testament to the mechanistic generality of transcriptional activation by ElA.
It can be inferred from our discussions given above that the ElA protein plays a direct role in enhancing transcription from the VAl promoter. It has been suggested (40) that ElA transactivates the VAl gene by effectively increasing the concentration of TFIIIC, the rate-limiting factor of VAl transcription (24) . However, the results presented herein show that this is not the case; instead, they argue for a more direct involvement between these two proteins. This is a reasonable notion in view of recent reports indicating that TFIIIC can be of two distinct forms, one of which appears to have greater transcriptional activity in vitro and a tendency to associate more rapidly (-1 min) with its cognate binding site (the B-block region) on the VAl promoter. The other form of TFIIIC does not appear to be committed to transcriptional activity, and although the B-block element provides a binding site for it as well, maximal association usually occurs after 40 min (18) . Our finding here that the levels of transcription from the VAl promoter decrease appreciably in HeLa whole-cell extracts initially incubated with a 175-or 350-fold molar excess of B-block oligonucleotide and not with an equivalent amount of a nonspecific oligonucleotide (Fig. 3A) is somewhat consistent with these earlier reports. Conceivably, this change in VAl transcription could be a result of the unavailability of active TFIIIC molecules depleted by virtue of its rapid association with the B-block oligonucleotide. If what remains is mostly TFIIIC molecules that are transcriptionally inactive (18) , then this may be one reason why purified ElA is able to specifically restore the levels of VAl transcription when added to whole-cell extracts initially incubated with the B-block oligonucleotide (Fig. 3B) . In effect, the ElA protein could be stimulating VAl transcription by operating through this particular form of TFIIIC. Not to be excluded, however, is the possibility that ElA may be affecting a set number of transcriptional complexes by making them more active in multiple rounds of transcription. This, nevertheless, defines a mechanism in contrast to that which has been recently reported (23) , whereby ElA is instrumental in increasing the number of preinitiation complexes active in VAl transcription. We also observed that restoration of VAl transcription by ElA could be thwarted if the extract was challenged with a second round of B-block oligonucleotide prior to the addition of the DNA template (Fig. 3C) . The implication of this last observation is twofold. First, ElA does not appear to be acting exclusively by itself at the VAl promoter; second, it rules out the possibility of other mechanistic pathways being important to ElA's transactivating activities.
Exactly how does the ElA protein stimulate VAl transcription through the TFIIIC factor? One possibility is that ElA either directly or indirectly alters TFIIIC through some form of modification such that it can no longer participate in the formation of a transcriptionally inactive complex. Consistent with this speculation is the recent finding that ElA expression in infected cells effects an increase in the con-centration of complexes formed between the VAl promoter and a transcriptionally active TFIIIC. Under these circumstances, very little, if any, of a complex consisting of inactive TFIIIC was detected, even though this particular complex had been shown to occur in uninfected cells (5, 18) . The interconversion of these two complexes, whereby one increases in amount presumably at the expense of the other, is believed to be influenced by phosphorylation, and it has been suggested that ElA may be playing a role in this activity (18) . Our next set of results, which reveals the effects of exogenous ElA on TFIIIC while interacting at the VAl promoter, appears to support these observations. Most significant in this regard is the finding by gel shift analysis of a TFIIIC-specific complex (Fig. 4A and B) that becomes consistently reduced in quantity when purified ElA is preincubated with either HeLa nuclear or whole-cell extracts (Fig. 5A) (data not shown) . This complex, whose formation is effectively blocked by ElA, is most likely equivalent to the one defined earlier (5, 18) which is generated by inactive TFIIIC. At this time, we have no clear evidence that ElA participates in the binding of the active form of TFIIIC to its site on the promoter or, for that matter, that a complex of this nature, with lower mobility, has been formed (5, 18) . However, the possibility of it being produced and increased in abundance by the action of ElA cannot be eliminated, since under the present analysis its appearance would most likely be obscured by complex A (Fig. 4A, lane 1) , whose composition does not include TFIIIC. In fact, the quantity of complex A does appear to be greater than that in extracts lacking ElA (Fig. 5A ), although to a very small degree as judged by densitometry. To properly conclude, however, that this phenomenon is truly occurring, it will be necessary to examine the effect of purified ElA in fractionated extracts; experiments of this nature are now under way in our laboratory. The alternative, that ElA binds directly to TFIIIC in a manner reminiscent of the protein-protein interaction of herpes simplex virus VP16 and the host cell transcription factor OTF-1 (12), seems unlikely. For the most part, no novel TFIIIC-promoter complexes exhibiting reduced electrophoretic mobility were observed after ElA was preincubated in nuclear or whole-cell extracts (Fig. 5A and B and data not shown). This implies that ElA does not interact directly with the VAl promoter through physical association with assembled transcriptional factors on the promoter, as has been previously proposed for the promoters of class II genes (28, 29, 31) . Taken together, our observations can be best explained by assuming that ElA mediates a qualitative change in TFIIIC, which in turn affects its DNA-binding properties and, possibly, transcriptional activities.
It seems very likely that under the assay conditions used here, ElA is directly responsible for somehow altering the physical nature of TFIIIC, since its effect on the TFIIICcontaining complex can be readily neutralized when E1A-specific antibody is added to nuclear extracts together with ElA (Fig. SB) . Further, whatever mechanism ElA may be using to transcriptionally activate TFIIIC, it appears to be quite rapid and permanent, since the use of antibody appears to have no effect on ElA if it is added to nuclear extracts at a much later time.
Since at present our purified ElA has not been shown to have any kinase activity (17a), we believe that it serves more as a passive communicator in the pathway of POLIII transcriptional regulation. Whether 
